


Greater options
for more flexibility



PERFORMANCE through innovation


Now Available in
6 Fr

**THE CONTINUING EVOLUTION
OF A REVOLUTIONARY DEVICE**



VIABAHN[®]
ENDOPROSTHESIS

HEPARIN
BIOACTIVE SURFACE



Lower French Sizes

- Reduced delivery profile for 5 – 8 mm devices

| DIAMETER (mm) | PROFILE (Fr) | GUIDEWIRE |
|---------------|--------------|------------------|
| 5 | 6 | 0.014" or 0.018" |
| 6 | 6 | 0.014" or 0.018" |
| 7 | 7 | 0.014" or 0.018" |
| 8 | 7 | 0.014" or 0.018" |



- New catheter design maintains pushability and trackability of previous generation



▶ **The Endoluminal Bypass**

ePTFE Lining

Provides barrier to in-stent restenosis

Nitinol Stent


Unique stent-graft design is conformable and durable in the dynamic SFA

CARMEDA® BioActive Surface (CBAS® Surface)

Intended to provide thromboresistant surface

Contoured Proximal Edge

May improve flow dynamics as blood enters endoprosthesis



▶ **Streamlined Deployment for All Configurations: 5 – 13 mm diameters**

- TIP to HUB deployment
- Radial endoprosthesis expansion
- 0.035" guidewire compatibility

▶ CARMEDA® BioActive Surface (CBAS® Surface)

- Intended to provide a thromboresistant surface
- Sustained bioactivity*
- Proprietary end-point covalent bonding

GORE® VIABAHN® Endoprosthesis
with Heparin Bioactive Surface




The bioactive luminal surface of a 5 mm diameter GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface appears free of thrombus after two hours in an in vitro blood loop model.

Control Endoprosthesis



The non-bioactive luminal surface of a control endoprosthesis (5 mm diameter) appears covered with thrombus after 90 minutes in the same blood loop model (data on file).

▶ Sustained Bioactivity



Long-term Heparin Activity of Explanted Heparin-bonded ePTFE Vascular Grafts in a Canine Model*


* Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® bioactive surface heparin immobilization. *European Journal of Vascular and Endovascular Surgery* 2003;25(5):432-437.




Proprietary End-Point Covalent Bonding

Only the end of the heparin molecule is bonded to the endoprosthesis surface


- The heparin bioactive sites remain free to interact with the blood



- *Heparin molecules are bonded to the endoprosthesis surface*
- *Bioactive site of the heparin molecule binds to antithrombin (AT)*



- *Antithrombin binds to thrombin (T) – a neutral AT-T complex is formed*
- *Thrombin loses its ability to catalyze the conversion of fibrinogen to fibrin*




- *Neutral AT-T complex detaches from the heparin molecule*
- *Heparin bioactive site becomes available to again bind antithrombin*


▶ Contoured Proximal Edge

- Precision laser trimming technology enables manufacturing change
- Excess material at the proximal edge removed
- Improves device apposition to the vessel wall when oversizing prevents device expansion to its nominal diameter
- Contoured edge may improve flow dynamics at proximal end

CANINE IN VIVO IVUS EXAMPLES



ANIMAL ACUTE EXAMPLES







W. L. GORE & ASSOCIATES, INC.

Flagstaff, AZ 86004

+65.67332882 (Asia Pacific) 800.437.8181 (United States)
00800.6334.4673 (Europe) 928.779.2771 (United States)

goremedical.com

INTENDED USE / INDICATIONS The GORE® VIABAHN® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.0 – 7.5 mm. The GORE® VIABAHN® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in iliac artery lesions with reference vessel diameters ranging from 4.0 – 12 mm. **CONTRAINDICATIONS** The GORE® VIABAHN® Endoprosthesis is contraindicated for non-compliant lesions where full expansion of an angioplasty balloon catheter was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system. Do not use the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface in patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of Heparin-Induced Thrombocytopenia (HIT) type II. Rx Only

Products listed may not be available in all markets.
GORE®, GORE-TEX®, HEMOBAHN®, VIABAHN®, and designs are trademarks of W. L. Gore & Associates.
CARMEDA® and CBAS® are trademarks of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates.
EXCOR® is a registered trademark of BerlinHeart GmbH.
© 2007 – 2011 W. L. Gore & Associates, Inc. AL0342-EN3 MARCH 2011